Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants

Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair.

Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms.

Study Overview

• Status: Completed
• Conditions: Crohn's Disease
• Intervention / Treatment: Drug: Prochymal™ adult human mesenchymal stem cells; Drug: adult human mesenchymal stem cells

Detailed Description

Human mesenchymal stem cells (MSCs), derived from healthy adult volunteer human donors, can be obtained from bone marrow donation and cultured in the laboratory. MSCs have shown the ability to find injured tissue, reduce and control inflammation, and assist in tissue repair.

Prochymal™ MSCs will be infused into patients with moderate-to-severe Crohn's disease. Infusions will occur on two separate days, 7-10 days apart. Patients will be monitored for reduced Crohn's disease symptoms. Patients will receive high or low dose. Study is open label.

• Study Type: Interventional
• Enrollment (Actual): 10
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Louisiana
    • Baton Rouge, Louisiana, United States, 70801
      • Osiris Clinical Site
  • North Carolina
    • Charlotte, North Carolina, United States, 28105
      • Osiris Clinical Site
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15106
      • Osiris Clinical Site
  • Virginia
    • Richmond, Virginia, United States, 23173
      • Osiris Clinical Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 68 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subject must be 18 to 70 years of age, inclusive.
2. If female and of child-bearing age, subject must be non-pregnant, non-breast-feeding, and use adequate contraception. If male, subject must use adequate contraception.
3. Subject must have endoscopically or radiographically active Crohn's disease
4. Subject must have a Crohn's disease activity index (CDAI) of at least 220.
5. Subject must have a C-reactive protein (CRP) of at least 5 mg/l.
6. Subject must have ileocolitis, colitis, or ileitis.
7. At some time during the course of the subject's Crohn's disease (CD), subject must have received both steroids and immunosuppressive agents (for example, azothioprine, 6-mercaptopurine, or methotrexate) which did not control the CD.

8. Subject may be receiving antibiotics, 5-aminosalicylic acid, azathioprine, 6-mercaptopurine, methotrexate, prednisone, or any similar drugs at the time of enrollment.

   • The dose of 5-aminosalicylic acid (5-ASA) must have been stable for at least 4 weeks prior to enrollment.
   • The dose of steroids must have been stable for at least 4 weeks prior to enrollment.
   • The dose of antibiotics must have been stable for at least 4 weeks prior to enrollment.
   • The dose of immunosuppressants (for example, azathioprine, 6-mercaptopurine [6-MP], or methotrexate) must have been stable for at least 8 weeks prior to enrollment and the subject on therapy for at least three months prior to enrollment.
9. Subject must have adequate renal function as defined by a calculated creatinine clearance of greater than 30 ml/min using the Cockcroft-Gault equation, and a serum creatinine concentration of less than 2.0 mg/dl.
10. Subject must be available for all specified assessments at the study site through day 30.
11. Subject must provide a written informed consent form (ICF) and authorization for use of and disclosure of personal health information (PHI).

Exclusion Criteria:

1. Subject has any alcohol or substance abuse within 6 months of randomization.
2. Subject has evidence of fibrostenotic obstructive Crohn's disease.
3. Subject has an active infection with HIV or hepatitis B or C.
4. Subject has had surgery or trauma within 28 d prior to enrollment.
5. Subject has a known allergy to computed tomography (CT) contrast agents.
6. Subject has a known allergy to bovine or porcine products.
7. Subject has body mass greater than 150 kg.
8. Subject has had a stricture of the bowel requiring hospitalization within 6 months prior to enrollment.
9. Subject has had bowel surgery other than perianal (for example, fistulotomy, seton placement, or abscess drainage) within 6 months prior to enrollment.
10. Subject has received infliximab; adalimumab; or other antibody, protein, or biological therapy not specifically approved by the United States Food and Drug Administration (FDA) for Crohn's disease for 90 days (d) prior to enrollment in study.
11. Subject has received prednisone greater than 20 mg/d at any time 28 d prior to enrollment in study.
12. Subject has a permanent colostomy or ileostomy.
13. Subject has aspartate aminotransferase (AST), alkaline phosphatase (ALP), or alanine transaminase (ALT) more than 2.5 times the upper limit of normal at screening.
14. Subject has evidence of active malignancy other than resected basal or squamous cell carcinoma of the skin, or prior history of active malignancy that has not been in remission for at least 5 years.
15. Subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months other than a treated urinary tract infection or drained perianal abscess.
16. Subject has received an investigational agent (IA)-an agent or device not approved by FDA for marketed use in any indication-within 90 d (or 5 half-lives, whichever is longer) of randomization.
17. Subject has cardiopulmonary disease that, in the opinion of the Investigator, is either unstable or severe enough to justify exclusion from this study.
18. Subject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would make participation in the study unsafe.
19. Subject has any underlying or current medical or psychiatric condition that, in the opinion of the Investigator, would interfere with the evaluation of the subject. Such excluding conditions might include, for example, uncontrolled infection, right heart failure, pulmonary hypertension.
20. Subject has unstable arrhythmia.
21. Subject is unwilling or unable to adhere to requirements of protocols.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: High dose; High dose (8 million cells per kg of body weight)	Drug: Prochymal™ adult human mesenchymal stem cells; Cells in plasmalyte and containing dimethylsulfoxide; Other Names: PROCHYMAL; Drug: adult human mesenchymal stem cells; two infusions, one week apart, each comprising adult human mesenchymal stem cells; Other Names: PROCHYMAL
Experimental: Low dose; Low dose: 2 million cells per kg body weight	Drug: Prochymal™ adult human mesenchymal stem cells; Cells in plasmalyte and containing dimethylsulfoxide; Other Names: PROCHYMAL; Drug: adult human mesenchymal stem cells; two infusions, one week apart, each comprising adult human mesenchymal stem cells; Other Names: PROCHYMAL

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Reduction in Crohn's Disease Activity Index (CDAI) of at Least 100 Points	The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.	28 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants with Reduction in CDAI of at Least 70 points	The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.	28 days
Improvement as Assessed by the Inflammatory Bowel Disease Questionnaire (IBDQ)	The IBDQ measures disease-specific quality of life by assessing bowel symptoms, systemic symptoms, emotional function, and social function. Subscores can range from 1 (worst) to 7 (best). The total IBDQ is calculated as the sum of the responses to the individual IBDQ questions. The total score ranges from 32 to 224. An increase in score from baseline indicates improvement.	28 days
Time to Improvement in IBDQ		28 days
Number of Participants with Reduction of at Least 50% in Fistulas in Participants with Fistulas Draining Under Moderate Compression		28 days
Number of Participants with Induction of Remission as Defined by Reduction of CDAI to Below 150	The CDAI is a composite index of 8 disease variables (stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations or fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight). Scores range from approximately 0 to 600, with a higher score indicating more disease activity.	28 days
Time to Reduction in CDAI of at Least 100 Points		28 days
Time to Reduction in CDAI of at Least 70 Points		28 days
Time to Induction of Remission as Defined by Reduction of CDAI to Below 150.		28 days
Number of Participants with Adverse Events		Up to approximately 2 years

Collaborators and Investigators

• Sponsor: Mesoblast, Inc.
• Investigators: Study Director: Mahboob Rahman, MD, Mesoblast, Inc.

Study record dates

Study Major Dates

• Study Start (Actual): March 13, 2006
• Primary Completion (Actual): July 21, 2006
• Study Completion (Actual): July 21, 2006

Study Registration Dates

• First Submitted: February 17, 2006
• First Submitted That Met QC Criteria: February 17, 2006
• First Posted (Estimate): February 20, 2006

Study Record Updates

• Last Update Posted (Actual): April 2, 2020
• Last Update Submitted That Met QC Criteria: March 31, 2020
• Last Verified: March 1, 2020

More Information

Terms related to this study

• Keywords: mesenchymal stem cells
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Intestinal Diseases; Inflammatory Bowel Diseases; Crohn Disease; Anti-Infective Agents; Antiviral Agents; Anti-Inflammatory Agents; Remestemcel-l
• Other Study ID Numbers: OSIRIS-601-602

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No